|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9544
|
|
pubmed:dateCreated |
2006-10-18
|
|
pubmed:abstractText |
6-mercaptopurine has been a standard component of long-term continuing treatment for childhood lymphoblastic leukaemia, whereas 6-thioguanine has been mainly used for intensification courses. Since preliminary data have shown that 6-thioguanine is more effective than 6-mercaptopurine, we compared the efficacy and toxicity of the two drugs for childhood lymphoblastic leukaemia.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
14
|
|
pubmed:volume |
368
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1339-48
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17046466-6-Mercaptopurine,
pubmed-meshheading:17046466-Adolescent,
pubmed-meshheading:17046466-Antimetabolites, Antineoplastic,
pubmed-meshheading:17046466-Child,
pubmed-meshheading:17046466-Child, Preschool,
pubmed-meshheading:17046466-Disease-Free Survival,
pubmed-meshheading:17046466-Female,
pubmed-meshheading:17046466-Follow-Up Studies,
pubmed-meshheading:17046466-Humans,
pubmed-meshheading:17046466-Infant,
pubmed-meshheading:17046466-Male,
pubmed-meshheading:17046466-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:17046466-Thioguanine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
|
|
pubmed:affiliation |
Department of Paediatric Haematology, Sheffield Children's Hospital, Sheffield S10 2TH, UK. ajay.vora@sch.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
